Canaan IX L.P.'s Net Worth
$105 Million
Who is Canaan IX L.P.?
Canaan IX L.P. has an estimated net worth of $105 Million. This is based on reported shares across multiple companies, which include TheRealReal, Inc., ARVINAS INC., and CytomX Therapeutics, Inc..
SEC CIK
Canaan IX L.P.'s CIK is 0001538676
Past Insider Trading and Trends
2019 was Canaan IX L.P.'s most active year for acquiring shares with 6 total transactions. Canaan IX L.P.'s most active month to acquire stocks was the month of June. 2019 was Canaan IX L.P.'s most active year for disposing of shares, totalling 7 transactions. Canaan IX L.P.'s most active month to dispose stocks was the month of June. 2018 saw Canaan IX L.P. paying a total of $0.00 for 4,989,554 shares, this is the most they've acquired in one year. In 2018 Canaan IX L.P. cashed out on 16,216,057 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
TheRealReal, Inc. (REAL) Snapshot price: $2.25
InvestorCanaan IX L.P. owns 7,925,919 units of Common Stock which is worth $17,833,317.75. In the year 2019 Canaan IX L.P. filed a total of 3 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -10.00% | -881.00K |
—
|
—
| 7.93M |
Jan 14
| |||
Form 4
| +1,647.37% | 8.3M |
—
|
—
| 8.81M |
Jul 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARVINAS INC. (ARVN) Snapshot price: $24.4
InvestorCanaan IX L.P. owns 3,589,554 units of Common Stock which is worth $87,585,117.60. In the year 2018 Canaan IX L.P. filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -10.03% | -400.00K |
—
|
—
| 3.59M |
Oct 14
| |||
Form 4
| -11.14% | -500.00K |
—
|
—
| 3.99M |
Jul 20
| |||
Form 4
| -10.02% | -500.00K |
—
|
—
| 4.49M |
Jun 10
| |||
Form 4
|
∞
| 4.99M |
—
|
—
| 4.99M |
Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CytomX Therapeutics, Inc. (CTMX) Snapshot price: $1.2
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -23.12% | -750.00K |
—
|
—
| 2.49M |
Mar 27
| |||
Form 4
| -11.51% | -422.09K |
$11.18 |
—
| 3.24M |
Nov 29 - Nov 30
| |||
Form 4
| -1.04% | -38.46K |
$11.56 | -$444,404.44 | 3.67M |
Nov 23 - Nov 28
| |||
Form 4
| -1.14% | -42.55K |
$11.71 | -$498,077.53 | 3.7M |
Nov 22
| |||
Form 4
| -1.20% | -45.32K |
$11.61 | -$526,087.76 | 3.75M |
Nov 17 - Nov 21
| |||
Form 4
| -1.34% | -51.58K |
$11.50 | -$593,428.35 | 3.79M |
Nov 15 - Nov 16
| |||
Form 4
| -2.19% | -86.27K |
$11.16 | -$962,906.75 | 3.84M |
Nov 10 - Nov 14
| |||
Form 4
| -0.35% | -13.73K |
$11.03 | -$151,498.19 | 3.93M |
Nov 9
| |||
Form 4
| -7.07% | -300.00K |
—
|
—
| 3.94M |
Oct 11
| |||
Form 4
| -1.13% | -48.43K |
$10.07 | -$487,498.32 | 4.24M |
Jun 8 - Jun 10
| |||
Form 4
| -2.53% | -111.50K |
$10.01 | -$1,116,289.60 | 4.29M |
Jun 6 - Jun 7
| |||
Form 4
| -1.34% | -59.62K |
$10.80 | -$644,047.71 | 4.4M |
Jun 2 - Jun 3
| |||
Form 4
| -0.50% | -22.46K |
$10.75 | -$241,477.25 | 4.46M |
Jun 1
| |||
Form 4
| -0.56% | -25.08K |
$10.60 | -$265,869.20 | 4.49M |
May 27
| |||
Form 4
| -1.13% | -51.34K |
$10.34 | -$530,810.53 | 4.51M |
May 25 - May 26
| |||
Form 4
| -0.29% | -13.25K |
$10.09 | -$133,735.30 | 4.56M |
May 23 - May 24
| |||
Form 4
| -0.19% | -8.69K |
$10.10 | -$87,776.83 | 4.58M |
May 19 - May 20
| |||
Form 4
| -6.14% | -300.00K |
—
|
—
| 4.58M |
Apr 25
| |||
Form 4
|
∞
| 4.88M |
—
|
—
| 4.88M |
Oct 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||